tachyarrhythmia, which would explain the symptoms experience by the patient. A significantly elevated troponin however, could not be explained by a tachyarrhythmia alone. One hypothesis for developing an acute coronary syndrome, is the vasodilatation role of TNF in the maintenance of myocardial vascular perfusion through the induction of nitric oxide. It is also capable of inhibiting apoptosis of myocardiocytes and attenuation of cardiac stimulation by the sympathetic nervous system through breceptors. The administration of Infliximab, which is a potent anti-TNF antibody can neutralise both soluble and membrane-bound TNF which can suspend these homeostatic mechanisms, resulting in deprivation of first line defences and leading to coronary vasoconstriction and hypoperfusion. Why patients without prior cardiovascular disease develop such symptoms isstill unclear and maybe a further scope for research. Key Learning Points: Potent anti-TNF agents have the theoretical ability of causing coronary vasoconstriction and hypoperfusion. Albeit rare, patients presenting with chest pain, during or after the infusion should have the appropriate coronary biochemistry and investigations performed. Young people with no risk of cardiovascular disease can develop transient acute coronary syndrome in response to potent anti-TNF agents. Doubling the frequency of infusion in attempt to regain control of disease after secondary failure should be done with caution and may increase the risk. Introduction: Behc¸et's disease (BD) is an idiopathic, multi system, autoinflammatory vasculopathic disorder, characterised by mouth and genital ulcers, rash, arthritis and uveitis. Ocular manifestations occur in up to 80% of patients and are associated with 30% risk of blindness. We present a challenging case of an adolescent with paediatric onset BD and aggressive refractory uveitismainly affecting the left eye. Case description: An 11 year old girl presented acutely with a three day history of a painful red left eye and blurred vision. Examination revealed bilateral uveitis with optic disc swelling, cystoid macular oedema (worse in left eye), 2 plus cells in her right eye, 3 plus cells in her left eye (according to standardisation of uveitis nomenclature classification) with snowballs and reduced visual acuity. A two-year history of mouth and genital ulcers wasgiven andatpresentationmild arthritiswas detected.Initialtreatment with intravenous methylprednisolone (IVMP), intensive topical steroid eye drops and subcutaneously administered methotrexate (15mg/m
A CHALLENGING CASE OF REFRACTORY BEHÇ ET'S DISEASE IN AN ADOLESCENT WITH SIGHT THREATENING UVEITIS
Introduction: Behc¸et's disease (BD) is an idiopathic, multi system, autoinflammatory vasculopathic disorder, characterised by mouth and genital ulcers, rash, arthritis and uveitis. Ocular manifestations occur in up to 80% of patients and are associated with 30% risk of blindness. We present a challenging case of an adolescent with paediatric onset BD and aggressive refractory uveitismainly affecting the left eye. Case description: An 11 year old girl presented acutely with a three day history of a painful red left eye and blurred vision. Examination revealed bilateral uveitis with optic disc swelling, cystoid macular oedema (worse in left eye), 2 plus cells in her right eye, 3 plus cells in her left eye (according to standardisation of uveitis nomenclature classification) with snowballs and reduced visual acuity. A two-year history of mouth and genital ulcers wasgiven andatpresentationmild arthritiswas detected.Initialtreatment with intravenous methylprednisolone (IVMP), intensive topical steroid eye drops and subcutaneously administered methotrexate (15mg/m 2 ) was commenced. Infliximab (6 mg/Kg intravenously four-weekly) and mycophenolate mofetil (MMF, 600mg/m 2 orally twice-daily) were subsequently added for multi-focal chorioretinitis in the left temporal retina. Infliximab was changed to tocilizumab (8mg/Kg intravenously 2-weekly) in response to reduced vision as a result of persisting chronic cystoid macular oedema. Subsequently, tocilizumab was changed to adalimumab (40mg subcutaneously fortnightly), for repeated sight-threatening uveitis flare-ups. Fifteen months after initial presentation MMF and adalimumab were substituted for pulsed intravenous cyclophosphamide (initially 500mg/m 2 fortnightly, increasing to a maximum 1g/m 2 3-weekly; total 6 doses) for pseudo-hypopyon, recurrent widespread multi-focal chorioretinitis and acute sight loss (6/60).Multiple pulses of IVMP and oral prednisolone were given throughout the treatment course in response to repeated flare-ups of inflammation associated with reduced visual acuity due to macular oedema. Despite cyclophosphamide treatment, further severe flare-ups of eye disease complicated by pseudo-hypopyon, optic-disc swelling, multi-focal choroiditis and pseudo-necrotising retinitis occurred. Following cyclophosphamide, interferon-alfa-2A (roferon A, 3 million units subcutaneously daily) was commenced resulting in sustained and complete remission of eye inflammatory features including previously refractory cystic macular oedema; vision improved significantly to 6/9þ. Interferon-alfa-2A had been well tolerated and demonstrated clinical effectiveness from the first week. However, following further flares, the dose was increased to 6 million units subcutaneously daily. Ocular disease remained relatively stable for 6 months although the other BD manifestations, such as, mouth ulcers remained problematic. An acute episode occurred consisting of pseudo-hypopyon, panuveitis, multifocal choroiditis and exudative retinal detachment. During the course of the illness, two years and five months after presentation, the patient developed functional visual loss and was managed with psychology intervention. Eye inflammation improved significantly with pulsed IVMP, and continued to require IVMP.However, disease flares with recurrent skin rashes occurred. Recommendations were followed, from liaising closely with National Paediatric Behc¸et's Centre at Alder Hey Hospital. Methotrexate was discontinued, interferon-alfa-2A was discontinued and adalimumab 40mg started by weekly injection alongside azathioprine 50mg orally once daily, gradually increased to 125mg. Mouth and genital ulcers of BD have subsided although clinically the patient is now left with visual impairment in the left eye due to probable occlusive vasculitis related optic neuropathy. A well-planned and coordinated transition pathway is in process for this now adolescent patient. This involves a collaborative and iterative approach with both the adult uveitis team and the patient and family, to ensure that the psychological manifestations of this complex disease are addressed and well supported throughout the transition period and beyond. Throughout the treatment pathway we collaborated with colleagues in national centres of expertisefor paediatric BD and uveitis. Discussion: For this patient, it has been proven to be significantly challenging to achieve long lasting remission of the ocular manifestations in BD. However, the disease has always responded well to prompt interventions with pulsed IVMP. Key Learning Points: The challenges of treating Behc¸et's uveitis to achieve remission whilst preserving vision are well recognised. This case adds to the emerging evidence for the use of interferon-alfa-2A in treating Behc¸et's uveitis. The psychological impact of both the chronic diseases and treatment burden must be routinely assessed in the management of young people. A robust and well planned transition pathway is essential for adolescents with chronic complex disease processes such as Behc¸et's uveitis. Introduction: Takayasu arteritis is a chronic, granulomatous vasculitis of large vessels, involving the aorta and its major branches. Its aetiology is unknown and disease progression is variable with 10-year survival >90%. Takyasu arteritis is rare in children and young people (CYP). It is more frequent in Asian countries compared to Europe and North America, but the incidence is unknown. A 2010 review reported only 241 cases in CYP were reported worldwide. This case is of a 14 year old adolescent diagnosed with Takayasu arteritis six years ago aged eight. We outline the complex progression through his disease which has proved refractory to multiple treatments which themselves have caused morbidity. The case highlights many of the biomedical as well as psychosocial issues that can challenge teams looking after children and young people with rare conditions and the particular complexities that adolescence adds. Case description: The patient was born in 2004 and grew up as part of a travelling family living on a static site. He had no health or developmental problems until 2012 when he presented with fatigue, weight loss, back pain, swollen ankles, and daily fever. At the time of presentation he had no arthritis, no skin rash, and no neurological signs. His left brachial pulse was diminished and right dorsalis pedis was absent (clinically and by USS). His left carotid pulse was present, but the right diminished (by USS). There was a difference of 20mmHg in systolic blood pressure in his arms (elevated on the right). His ESR was 108. A CT chest showed a widened mediastinum and renal USS showed stenosis of both renal arteries, more on the left side. An MRA showed diffuse thickening to the walls of both common carotids and proximal internal carotid bilaterally with 50% stenosis of the right internal carotid artery. Based on these findings, he was diagnosed with Takayasu arteritis. The patient was started on treatment with corticosteroids (initially intravenous later orally), intravenous cyclophosphamide and subcutaneous methotrexate. He was commenced on low molecular weight heparin (LMWH) with a plan to switch to
